The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Combination Therapy for Non-Alcoholic Steatohepatitis: Rationale, Opportunities and Challenges
Gut. 2020 May 7;gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.Online ahead of print.
1Hepatology, Department of Clinical Research, University of Bern, Bern, Switzerland jean-francois.dufour@dbmr.unibe.ch.
2University Clinic for Visceral Surgery and Medicine, Inselspital, Bern, Switzerland.
3Centre Hospitalier Lyon Sud, Endocrinologie Diabète et Nutrition, University Lyon 1, Hospices Civils de Lyon, Lyon, France.
4NAFLD Research Center, University of California at San Diego, La Jolla, California, USA.
5Division of Gastroenterology and Hepatology, Department of Medicine, NAFLD Research Center, University of California at San Diego, La Jolla, California, USA.
Abstract
Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.